- Home
- COCO vs TVTX Comparison
COCO vs TVTX Comparison
Compare COCO & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCO
- TVTX
- Stock Information
- Founded
- COCO 2004
- TVTX 2008
- Country
- COCO United States
- TVTX United States
- Employees
- COCO N/A
- TVTX N/A
- Industry
- COCO Beverages (Production/Distribution)
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- COCO Consumer Staples
- TVTX Health Care
- Exchange
- COCO Nasdaq
- TVTX Nasdaq
- Market Cap
- COCO 2.0B
- TVTX 1.6B
- IPO Year
- COCO 2021
- TVTX N/A
- Fundamental
- Price
- COCO $35.86
- TVTX $17.37
- Analyst Decision
- COCO Buy
- TVTX Buy
- Analyst Count
- COCO 7
- TVTX 13
- Target Price
- COCO $32.33
- TVTX $23.46
- AVG Volume (30 Days)
- COCO 383.4K
- TVTX 1.4M
- Earning Date
- COCO 10-30-2024
- TVTX 02-13-2025
- Dividend Yield
- COCO N/A
- TVTX N/A
- EPS Growth
- COCO 56.82
- TVTX N/A
- EPS
- COCO 1.00
- TVTX N/A
- Revenue
- COCO $494,864,000.00
- TVTX $203,447,000.00
- Revenue This Year
- COCO $5.30
- TVTX $62.17
- Revenue Next Year
- COCO $11.62
- TVTX $56.38
- P/E Ratio
- COCO $35.84
- TVTX N/A
- Revenue Growth
- COCO 3.21
- TVTX 57.08
- 52 Week Low
- COCO $19.41
- TVTX $5.12
- 52 Week High
- COCO $37.88
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- COCO 54.04
- TVTX 43.48
- Support Level
- COCO $34.77
- TVTX $16.66
- Resistance Level
- COCO $37.57
- TVTX $19.20
- Average True Range (ATR)
- COCO 1.24
- TVTX 0.74
- MACD
- COCO -0.27
- TVTX -0.24
- Stochastic Oscillator
- COCO 40.65
- TVTX 23.24
About COCO The Vita Coco Company Inc.
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. Geographical presence of the company is in United States, Canada, Europe, Middle East, Africa, and the Asia Pacific regions.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.